Research Professor, Department of Medicine
Our research involves clinical studies of a novel vaccine strategy for treating metastatic malignant melanoma. We have developed a method of inducing cellular immune responses to metastatic melanoma that result in frequent and durable complete regressions of disease.
We are also interested in immunological and virological aspects of HIV infection. We have investigated HIV-specific cellular immune responses in acute, primary HIV infection and in “elite controllers,” individuals who spontaneously control HIV without antiretroviral drugs. We have discovered that individuals treated very early in their HIV infection develop strong CD4+ T-cell memory responses to HIV antigens that are similar to, though often of lesser magnitude, than the memory responses observed in elite controllers. Some individuals who started antiretroviral drugs during the first few weeks of their HIV infection are, after one year of treatment, subsequently able to control their blood levels of HIV for one to two years (and sometimes longer) after stopping their anti-HIV drugs. Our study indicated that very early treatment improves the immune system’s ability to control HIV, although all patients should continue their anti-HIV drugs at all times.
MD from Harvard University
Fellowship, NYU School of Medicine, Infectious Diseases and Immunology
Residency, Harvard Medical Service Boston City Hospital, Internal Medicine
Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2015 Aug 25; 112(34):E4762-71
Pediatric infectious disease journal. 2012 Jul; 31(7):732-5
Clinical infectious diseases. 2011 Sep; 53(5):490-6
Blood. 2010 Nov 11; 116(19):3839-52
American journal of tropical medicine & hygiene. 2010 Sep; 83(3):565-70
Journal of infectious diseases. 2010 Mar 15; 201(6):843-54
Open AIDS journal. 2010 Mar 05; 4:76-83